BCL2 and hepatocellular carcinoma: For example, miR-181b that reduces BCL2 expression overcomes MDR by facilitating apoptosis in several MDR cancer cell lines.51 miR-181d also targets BCL2 to induce apoptosis and cell cycle arrest.52 Refractive B-cell MDR malignancy can be treated by inducing miR-125b and miR-155-mediated BCL2 suppression.53 BCL2-specific miRNAs also induce apoptosis in other cancer cells, whether MDR or not, for example, miR-125b in hepatocellular carcinoma (HCC) cells,54 miR-7 in the non-small cell lung cancer cell line A549 cells55 and miR-497 in gastric and lung cancer cell lines.56